Status:
UNKNOWN
Intravenous Iron Infusion on Chemotherapy-induced Anemia
Lead Sponsor:
Korea University Guro Hospital
Collaborating Sponsors:
Pharmbio Korea Inc.
Conditions:
Colon Cancer
Chemotherapeutic-Induced Anemia
Eligibility:
All Genders
18-80 years
Phase:
PHASE2
Brief Summary
FOLFOX, the first-line regimen based on 5-FU and oxaliplatin, is adjuvant chemotherapy for pathologic stage II/III colorectal cancer patients. Among various side effects of FOLFOX, chemotherapy-induce...
Eligibility Criteria
Inclusion
- \* clinical diagnosis of stage II or III after curative resection for colon cancer and planned to be received modified FOLFOX6 as an adjuvant chemotherapy
- more than 18 years old
- baseline Hb level \<12g/dL or more Hb 2g/dL decrease after chemotherapy
- patients who received more than 1 cycle of FOLFOX6
Exclusion
- \* patients with neoadjuvant therapy
- patients who have other diseases associated with anemia such as CKD, IBD, other bone marrow diseases
- patients who received RBC transfusion during chemotherapy
- patients diagnosed with local recurrence or distant metastasis during chemotherapy
- ferritin \> 800 ng/mL and TSAT ≧ 50%
- patients who are not willing to participate in the study
Key Trial Info
Start Date :
April 20 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT05299411
Start Date
April 20 2023
End Date
December 31 2025
Last Update
March 29 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.